IPR: Novartis’ cancer drug is not patentable, says appellate board Company reviewing decision and looking at various options. Mumbai, July 4 The Intellectual Property Appellate Board (IPAB) has said that Novartis’ cancer drug Glivec (Imatinib Mesylate) is not patentable in the beta crystalline ...